Association of clinical symptoms and cardiometabolic dysregulations in patients with schizophrenia spectrum disorders

Patients with schizophrenia spectrum disorders (SSD) have a shortened life expectancy related to cardiovascular diseases. We investigated the association of cognitive, positive, and negative symptoms with cardiometabolic dysregulations in SSD patients. Overall, 1,119 patients from the Genetic Risk a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European psychiatry Jg. 67; H. 1; S. e7
Hauptverfasser: Zhao, Chenxu, Habtewold, Tesfa Dejenie, Naderi, Elnaz, Liemburg, Edith J., Bruggeman, Richard, Alizadeh, Behrooz Z.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Cambridge University Press 13.12.2023
Schlagworte:
Antipsychotics
Biomarkers
Blood pressure
cardiometabolic biomarkers
Cardiovascular Diseases
Cholesterol
cognition
Cognitive ability
Glucose
Glycated Hemoglobin
Health risk assessment
High density lipoprotein
Humans
Lipoproteins
Longitudinal studies
Memory
metabolic syndrome
Metabolism
Psychosis
Psychotic Disorders - diagnosis
psychotic symptoms
Psychotropic drugs
Risk Factors
Schizophrenia
Schizophrenia - complications
Schizophrenia - drug therapy
Triglycerides
metabolic syndrome
psychotic symptoms
schizophrenia
cardiometabolic biomarkers
cognition
ISSN:0924-9338, 1778-3585, 1778-3585
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients with schizophrenia spectrum disorders (SSD) have a shortened life expectancy related to cardiovascular diseases. We investigated the association of cognitive, positive, and negative symptoms with cardiometabolic dysregulations in SSD patients. Overall, 1,119 patients from the Genetic Risk and Outcome in Psychosis (GROUP) study were included. Cognitive function, positive and negative symptoms were assessed at baseline, 3-year, and 6-year. Cardiometabolic biomarkers were measured at 3-year follow-up. We used linear and multinomial logistic regression models to test the association between cardiometabolic biomarkers and clinical trajectories and performed mediation analyzes, while adjusting for clinical and demographic confounders. Cognitive performance was inversely associated with increased body mass index (mean difference [β], β  = -1.24, 95% CI = -2.28 to 0.20,  = 0.02) and systolic blood pressure (β  = 2.74, 95% CI = 0.11 to 5.37,  = 0.04). The severity of positive symptoms was associated with increased glycated hemoglobin (HbA1c) levels (β  = -2.01, 95% CI = -3.21 to -0.82,  = 0.001). Increased diastolic blood pressure (OR  = 1.04, 95% CI = 1.01 to 1.08,  = 0.02; OR  = 1.04, 95% CI = 1.00 to 1.08,  = 0.048) and decreased high-density lipoprotein (OR  = 6.25, 95% CI = 1.81 to 21.59,  = 0.004) were associated with more severe negative symptoms. Increased HbA1c (OR  = 1.05, 95% CI = 1.01 to 1.10,  = 0.024; OR  = 1.08, 95% CI = 1.02 to 1.14,  = 0.006) was associated with more severe positive symptoms. These associations were not mediated by antipsychotics. We showed an association between cardiometabolic dysregulations and clinical and cognitive symptoms in SSD patients. The observed associations underscore the need for early identification of patients at risk of cardiometabolic outcomes.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
aDepartment of Psychiatry, Rijksuniversiteit Groningen, University Medical Center Groningen, Groningen,The Netherlands; bDepartment of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands; cUniversity Medical Center Utrecht, Department of Psychiatry, Brain Centre Rudolf Magnus, Utrecht University, Utrecht, The Netherlands; dUniversity Medical Center Utrecht, Department of Translational Neuroscience, Brain Center Rudolf Magnus, Utrecht, The Netherlands; eAmsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands; fMaastricht University Medical Center, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht, The Netherlands; gGGzE Institute for Mental Health Care, Eindhoven, The Netherlands; hKing’s College London, King’s Health Partners, Department of Psychosis Studies, Institute of Psychiatry, London, UK; iAltrecht, General Mental Health Care, Utrecht, The Netherlands; jGGNet Mental Health, Apeldoorn, The Netherlands; kArkin, Institute for Mental Health, Amsterdam, The Netherlands.
Genetic Risk and Outcome of Psychosis (GROUP) Investigators
Behrooz Z. Alizadeha,b, Therese van Amelsvoortf, Wiepke Cahnc,i, Lieuwe de Haane,k, Frederike Schirmbecke,k, Claudia J.P. Simonsf,g, Jim van Osd,h, Wim Velinga
ISSN:0924-9338
1778-3585
1778-3585
DOI:10.1192/j.eurpsy.2023.2477